The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Sep. 05, 2017

Filed:

Mar. 14, 2014
Applicant:

The Board of Trustees of the Leland Stanford Junior University, Stanford, CA (US);

Inventors:

Michael F. Clarke, Menlo Park, CA (US);

Maddalena Adorno, Palo Alto, CA (US);

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A01N 43/04 (2006.01); A61K 31/70 (2006.01); C12N 15/113 (2010.01); C12Q 1/68 (2006.01); A61K 31/7125 (2006.01); A61K 31/711 (2006.01); A61K 31/713 (2006.01); A61K 31/7088 (2006.01); A61K 31/712 (2006.01); A61K 31/7105 (2006.01); A61K 31/7115 (2006.01);
U.S. Cl.
CPC ...
C12N 15/1137 (2013.01); C12Q 1/6883 (2013.01); A61K 31/7088 (2013.01); A61K 31/711 (2013.01); A61K 31/712 (2013.01); A61K 31/713 (2013.01); A61K 31/7105 (2013.01); A61K 31/7115 (2013.01); A61K 31/7125 (2013.01); C12N 2310/14 (2013.01); C12N 2310/531 (2013.01); C12N 2320/30 (2013.01); C12N 2330/51 (2013.01); C12Q 2600/136 (2013.01); C12Q 2600/158 (2013.01); C12Q 2600/178 (2013.01); C12Y 301/02015 (2013.01);
Abstract

Methods and compositions are provided for the treatment of medical conditions associated with a reduced rate of stem cell self-renewal or that will be responsive to an increased rate of stem cell self-renewal. Aspects of the methods include inhibiting H2A deubiquitinating enzyme activity in cells, e.g. by administering an effective amount of an H2A deubiquitinating enzyme antagonist. Also provided are screens to identify therapeutics for the treatment of medical conditions associated with a reduced rate of stem cell self-renewal or that will be responsive to an increased rate of stem cell self-renewal.


Find Patent Forward Citations

Loading…